Articles tagged with Obinutuzumab
Pharmac Funds New Combination Therapies for Chronic Lymphocytic Leukaemia in NZ
1 month ago | 345 viewsAssociate Health Minister David Seymour applauds Pharmac’s decision to fund two new combination therapies—venetoclax with ibrutinib or obinutuzumab—as first-line treatments for chronic lymphocytic leukaemia (CLL), along with expanded access to ibrutinib as a second-line option. These treatments, available from May 2026, aim to improve patient outcomes by enabling longer remission, reducing the need for chemotherapy and hospital visits, and accommodating patient feedback gathered through community consultation. Since the government increased Pharmac’s budget, over 200,000 patients have benefited from funding decisions on 133 medicines, including 46 cancer treatments, reflecting a more collaborative approach with the patient community.
Tags: David Seymour Pharmac chronic lymphocytic leukaemia CLL venetoclax ibrutinib obinutuzumab cancer medication New Zealand cancer patientsPharmac Proposes Funding New Combination Therapies for CLL Blood Cancer in NZ
3 months ago | 465 viewsAssociate Health Minister David Seymour and Health Minister Simeon Brown support Pharmac’s proposal to fund two new combination therapies—venetoclax with ibrutinib, and venetoclax with obinutuzumab—as first-line treatments for chronic lymphocytic leukaemia (CLL) starting May 2026. These treatments aim to improve patient outcomes by enabling longer remission, reducing the need for chemotherapy, and offering more convenient pill-based options, including availability in private clinics to minimize patient disruption. The Government’s broader commitment includes investing $604 million to fund new blood cancer medicines, expanding stem cell transplant services, and enhancing cancer care access and timeliness across New Zealand.
Tags: David Seymour Simeon Brown Pharmac venetoclax ibrutinib obinutuzumab chronic lymphocytic leukaemia blood cancer New Zealand Government cancer treatment